Analysis review draft · AI-assisted · awaiting human editorial approval. This is not published reporting or an approved MOGanja opinion.
A newer report, an earlier sales year
The October 2026 DCR study provides a 2025 benchmark. It does not establish the direction of 2026 sales.
AI-assisted MOGanja draft · awaiting editorial review · Draft prepared October 30, 2026
What the verified series says
The DCR-commissioned market study reports $1.51B in retail sales for calendar 2025. Compared with the same table's 2024 figure, that is an increase of 3.2% in nominal dollars. This comparison uses two completed years and includes medical and adult-use retail sales.
That is evidence of a larger statewide sales total in 2025. It does not establish that every store grew, that sales volume rose, or that profitability improved. Revenue, units and margins answer different questions.
What remains unknown for 2026
MOGanja has not verified a 2026 monthly or year-to-date total from the official dashboard. Its sign-in requirement prevents checking that series through the currently available public view. The annual benchmark cannot fill that gap.
A valid current-year comparison needs the same months in both years, the same retail scope, and a record of any revisions. Comparing a partial year with a full year, or treating an import timestamp as a sales month, would give readers a misleading growth signal.
How we calculated this
- Source: DCR / CPPC Missouri Cannabis Market Study: Phase 1 Report, Table 14, printed page 50. Published October 15, 2026; source checked October 30, 2026.
- Calculation: (1,512,396,840.62 / 1,465,342,132.60 - 1) × 100; rounded to one decimal. No inflation adjustment. Figures are retail sales, not wholesale sales or tax revenue.
- The 2023 launch year is not used for this year-over-year comparison. No 2026 estimate, projection or October total is inferred.